CA3195380A1 - Compounds and methods for treating pain - Google Patents
Compounds and methods for treating painInfo
- Publication number
- CA3195380A1 CA3195380A1 CA3195380A CA3195380A CA3195380A1 CA 3195380 A1 CA3195380 A1 CA 3195380A1 CA 3195380 A CA3195380 A CA 3195380A CA 3195380 A CA3195380 A CA 3195380A CA 3195380 A1 CA3195380 A1 CA 3195380A1
- Authority
- CA
- Canada
- Prior art keywords
- amino acid
- seq
- pain
- subject
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Rheumatology (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063084358P | 2020-09-28 | 2020-09-28 | |
| US63/084,358 | 2020-09-28 | ||
| PCT/EP2021/076524 WO2022064043A1 (en) | 2020-09-28 | 2021-09-27 | Compounds and methods for treating pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3195380A1 true CA3195380A1 (en) | 2022-03-31 |
Family
ID=78085879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3195380A Pending CA3195380A1 (en) | 2020-09-28 | 2021-09-27 | Compounds and methods for treating pain |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240026036A1 (https=) |
| EP (1) | EP4217388A1 (https=) |
| JP (1) | JP2023543005A (https=) |
| KR (1) | KR20230084199A (https=) |
| CN (1) | CN117279942A (https=) |
| AU (1) | AU2021350424A1 (https=) |
| BR (1) | BR112023004840A2 (https=) |
| CA (1) | CA3195380A1 (https=) |
| IL (1) | IL301548A (https=) |
| TW (1) | TW202228768A (https=) |
| WO (1) | WO2022064043A1 (https=) |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| CA2975521A1 (en) | 2001-05-30 | 2002-12-05 | Genentech, Inc. | Anti-ngf antibodies for the treatment of various disorders |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| ZA200502612B (en) | 2002-10-08 | 2007-07-25 | Rinat Neuroscience Corp | Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same |
| US20080187954A1 (en) | 2004-03-10 | 2008-08-07 | Lonza Ltd. | Method For Producing Antibodies |
| CA2581208A1 (en) | 2004-08-30 | 2006-03-09 | Lonza Biologics Plc. | Affinity- plus ion exchange- chromatography for purifying antibodies |
| EP2298345A3 (en) | 2005-01-24 | 2012-03-21 | MedImmune Limited | Specific binding members for NGF |
| US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
| MX2010001395A (es) | 2007-08-10 | 2010-03-10 | Regeneron Pharma | Anticuerpos humanos de alta afinidad de factor de crecimiento de nervio humano. |
| EP2238154B1 (en) | 2008-01-18 | 2015-09-16 | Bio-Rad Laboratories, Inc. | Enhanced purification of phosphorylated and non-phosphorylated biomolecules by apatite chromatography |
| BR112012008833A2 (pt) * | 2009-10-15 | 2015-09-08 | Abbott Lab | imunoglobulinas de dominio variavel duplo e usos das mesmas |
| US9580509B2 (en) | 2011-11-07 | 2017-02-28 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
| LT3099713T (lt) * | 2014-02-02 | 2020-07-10 | Medimmune Limited | Chimerinis baltymas, sudarytas iš ngf antagonistinio domeno ir tnfa antagonistinio domeno |
| FI3863647T3 (fi) * | 2018-10-10 | 2024-03-01 | Paradigm Biopharmaceuticals Ltd | Pahanlaatuisen luustokivun hoitaminen pentosaanipolysulfaatilla |
-
2021
- 2021-09-27 KR KR1020237014327A patent/KR20230084199A/ko active Pending
- 2021-09-27 AU AU2021350424A patent/AU2021350424A1/en not_active Abandoned
- 2021-09-27 IL IL301548A patent/IL301548A/en unknown
- 2021-09-27 US US18/246,794 patent/US20240026036A1/en active Pending
- 2021-09-27 CN CN202180065320.3A patent/CN117279942A/zh active Pending
- 2021-09-27 BR BR112023004840A patent/BR112023004840A2/pt unknown
- 2021-09-27 JP JP2023519051A patent/JP2023543005A/ja active Pending
- 2021-09-27 WO PCT/EP2021/076524 patent/WO2022064043A1/en not_active Ceased
- 2021-09-27 CA CA3195380A patent/CA3195380A1/en active Pending
- 2021-09-27 EP EP21789613.3A patent/EP4217388A1/en active Pending
- 2021-09-28 TW TW110136070A patent/TW202228768A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL301548A (en) | 2023-05-01 |
| EP4217388A1 (en) | 2023-08-02 |
| CN117279942A (zh) | 2023-12-22 |
| BR112023004840A2 (pt) | 2023-04-18 |
| JP2023543005A (ja) | 2023-10-12 |
| WO2022064043A1 (en) | 2022-03-31 |
| AU2021350424A1 (en) | 2023-06-01 |
| KR20230084199A (ko) | 2023-06-12 |
| TW202228768A (zh) | 2022-08-01 |
| US20240026036A1 (en) | 2024-01-25 |
| AU2021350424A9 (en) | 2025-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11897949B2 (en) | Compounds and methods for treating pain | |
| US9644031B2 (en) | Epidermal growth factor receptor antibody | |
| US20210009671A1 (en) | Compounds and methods for treating pain | |
| CA3195380A1 (en) | Compounds and methods for treating pain | |
| HK40028980A (en) | Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain | |
| HK1231905A1 (en) | Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain | |
| HK1231905B (en) | Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain | |
| RU2788122C2 (ru) | Химерный белок, составленный из домена антагониста NGF и домена антагониста TNFα | |
| HK1234753A1 (en) | Compositions and methods for treating pain | |
| BR112016017698B1 (pt) | Molécula ligante, polinucleotídeo isolado, vetor, microrganismo transgênico, composição, kit, e, uso de uma molécula ligante |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250821 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250821 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250925 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250925 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250925 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251124 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20251124 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251124 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251124 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251124 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251125 |